296
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Global Burden of Asthma, and Its Impact on Specific Subgroups: Nasal Polyps, Allergic Rhinitis, Severe Asthma, Eosinophilic Asthma

ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon &
Pages 1097-1113 | Received 21 Apr 2023, Accepted 24 Sep 2023, Published online: 06 Oct 2023
 

Abstract

Background

The complex nature of asthma has resulted in a poor understanding of its epidemiology, particularly in low-and middle-income countries (LMIC). Clinical subgroups, such as patients with severe asthma, eosinophilic asthma, allergic rhinitis, or nasal polyps, experience additional barriers to care.

Methods

Prevalence estimates for asthma and key clinical subgroups were extracted from the Global Burden of Diseases, Injuries, and Risk Factors Study 2019 and from a targeted literature review conducted through PubMed in October of 2021. National estimates were calculated and the roles of potential explanatory factors were explored through qualitative analysis.

Results

In total, 162 publications from 69 countries were included. Across continents, asthma prevalence values ranged from 3.44% (Asia), 3.67% (Africa), 4.90% (South America), 5.69% (Europe), 8.29% (North America), to 8.33% (Oceania). Globally, of those with asthma, 26.70% had severe asthma, 30.99% had eosinophilic asthma, 48.95% had allergic rhinitis, and 7.0% to 25.40% had nasal polyps. Countries with higher air quality, income status, and healthcare access and quality reported a higher asthma prevalence.

Conclusion

Asthma prevalence values were low in LMICs, potentially indicating health system deficiencies resulting in low diagnosis and reporting. The prevalence of eosinophilic asthma and severe asthma phenotypes was high in many countries, although the prevalence estimates of all asthma subgroups were quite variable.

Data Sharing Statement

The corresponding author had access to all data in the study.

Disclosure

Professor Adrian Paul J Rabe was an employee of AstraZeneca during the conduct of the study. Dr Wei Jie Loke is an external research consultant who received personal fees from AstraZeneca UK, during the conduct of the study. Miss Khushboo Gurjar and Dr Allison Brackley were employees of Cytel Inc at the time of manuscript writing, which was hired by AstraZeneca to perform study analyses and development of this manuscript. The authors report no other conflicts of interest in this work.

Additional information

Funding

This study was funded by AstraZeneca (Cambridge, UK). AstraZeneca reviewed the publication, without influencing the opinions of the authors, to ensure medical and scientific accuracy, and the protection of intellectual property.